Objective: Netupitant is a novel, selective neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting, a distressing side effect of chemotherapy. This double-blind, randomized, Phase II study investigated the dose-response of oral netupitant in Japanese patients receiving highly emetogenic chemotherapy. Methods: Chemotherapy-naïve patients were randomized (1:1:1) to a single oral netupitant 30-, 100-or 300-mg dose before chemotherapy initiation. Patients received concomitant palonosetron (0.75 mg intravenously [i.v.] Day 1) and dexamethasone (9.9 mg i.v. Day 1, 8 mg orally Days 2-4). Results: Overall, 402 patients (30 mg: 134; 100 mg: 135; 300 mg: 133) were treated and evaluable for efficacy and safety. The primary endpoint of overall (0-120 h after chemotherapy administration) complete response (CR) rate (no emesis, no rescue medication) was 64.2%, 60.0% and 54.9% in the 30-, 100-and 300-mg arms, respectively, without statistical significance for dose-response.
Introduction
Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing side effects of chemotherapy, with a multifactorial pathophysiology involving several neurotransmitters and their receptors (1) . Therefore, effective CINV prevention is a clinically important issue for cancer patients receiving chemotherapy, as the condition may negatively affect adherence to treatment, as well as patients' quality of life (2) (3) (4) (5) .
Current antiemetic guidelines recommend the use of a triplet antiemetic regimen, which is composed of a neurokinin-1 receptor antagonist (NK 1 RA), a 5-hydroxytryptamine 3 (5-HT 3 ) RA, and dexamethasone for CINV prevention in cancer patients receiving highly emetogenic chemotherapy (HEC) including a combination of anthracycline and cyclophosphamide (AC) or carboplatin-based regimens, as well as in those with additional risk factors (6) (7) (8) (9) .
Aprepitant is actually the only available NK 1 RA that can be administered orally as an antiemetic agent in Japan. Aprepitant must be administered as a 3-day regimen (125 mg p.o. on Day 1, followed by 80 mg p.o. on Days 2 and 3), regardless of whether chemotherapy is scheduled on Days 2 and 3 or not.
Netupitant is a novel, highly selective NK 1 RA that has a longer plasma half-life than aprepitant (90 hours [h] vs 9-13 h, respectively) (10) (11) (12) ; this enables a single-dose administration of netupitant per chemotherapy cycle, prior to chemotherapy initiation. A large, pivotal, Phase II dose-ranging efficacy study (13) undertaken in Russia and Ukraine evaluated the efficacy and safety of netupitant at three dose levels (100, 200 and 300 mg p.o.). This study established that the optimal dose of netupitant is 300 mg, when administered in combination with palonosetron (0.5 mg p.o.), a clinically (5) and pharmacologically (14) distinct 5-HT 3 RA with a long plasma half-life (15) and dexamethasone (p.o.) in the HEC setting. A randomized, Phase III study confirmed the superiority of an oral, fixed-dose combination of netupitant/palonosetron (300 mg/0.50 mg) over palonosetron alone (0.50 mg p.o.) with regard to the primary endpoint of delayed complete response (CR) rate following doxorubicincyclophosphamide treatment (16) . Currently, netupitant (300 mg) has been approved by the US Food and Drug Administration and the European Medicines Agency as an oral fixed-dose form in combination with palonosetron (0.5 mg p.o.) for antiemetic prophylaxis in the HEC and moderately emetogenic chemotherapy settings.
A recent Phase I study of netupitant in healthy Japanese male volunteers demonstrated that the drug was well tolerated up to a dose of 600 mg following a single oral administration (data on file). The study also showed slightly supra-proportional increases in the maximum plasma concentration (C max ) of netupitant and area under the plasma concentration-time curve (AUC) for doses between 100 and 600 mg, similar to the pharmacokinetic profile observed in another study performed in a Caucasian population (17) .
The primary aim of this study was to assess the dose-response of three different netupitant doses (30, 100 and 300 mg) and, subsequently, to identify the optimal dose of netupitant in combination with 0.75 mg intravenous (i.v.) palonosetron (the approved dosage in Japan) and dexamethasone for further studies in Japanese cancer patients receiving HEC. The doses of netupitant used within this study were selected on the basis of tolerability, NK 1 receptor occupancy and the pharmacokinetic data from prior studies performed in healthy subjects (12) .
Materials and methods

Study design
This was a double-blind, randomized, parallel Phase II study conducted at 36 institutions in Japan, between March 2014 and December 2015. This study was approved by the review board at each participating institution and conducted according to the Declaration of Helsinki, International Conference on Harmonization, and Japanese Good Clinical Practice. All patients provided written informed consent.
Patient population
Patients aged ≥20 years with a histologically, cytologically or radiographically confirmed malignant tumor were eligible. All patients were chemotherapy naïve or had only received 1 prior low or minimally emetogenic chemotherapy regimen. , in the morning). Randomization was performed via an interactive Web-response system. A minimization method was applied to balance the three dose arms based on the allocation adjustment factors such as chemotherapy regimen (CDDP or AC or EC), sex (male vs female), and age (<55 vs ≥55 years). Rescue medication (excluding aprepitant, fosaprepitant meglumine, palonosetron and dexamethasone) for CINV was allowed if nausea or emetic episodes occurred, and was administered at the discretion of the investigator or in response to patient's desire.
The rescue medications allowed in the study were: 5-HT 3 RAs (excluding palonosetron), corticosteroids (excluding dexamethasone), dopamine D2-receptor antagonists, benzodiazepines (excluding on-demand use of very short-acting drugs for the treatment of sleeplessness), phenothiazine, anxiolytic agents, butyrophenones, 5-HT/D2 blockers, first-generation antihistamines, others (scopolamine, olanzapine, mirtazapine and octreotide). Supplementary Table 1 summarizes the rescue medications administered across the three arms of this study.
Study endpoints and assessments
The primary endpoint of this study was overall (0-120 h) CR rate. The secondary endpoints were: the rates of no vomiting, no nausea and no significant (moderate or severe) nausea (NSN); and safety (adverse events [AEs], adverse drug reactions [ADRs]), and pharmacokinetics. Daily CR rates experienced by the patients during the 0-120 h interval following administration of 30-, 100-or 300-mg netupitant were also assessed. The CR rate was defined as the proportion of patients with no emetic episode and no use of rescue antiemetic medication after the initiation of HEC therapy. Severity of nausea was measured by the 4-point Likert scale (none, mild, moderate or severe), which patients themselves recorded using a daily diary.
Patients underwent medical interviews, physical examinations, and blood tests before registration. Blood tests included complete blood count, as well as markers of liver and renal function. The efficacy endpoints were assessed during a 5-day observation period after chemotherapy initiation. Safety was assessed by AEs, clinical laboratory evaluations, physical examinations, vital signs and electrocardiograms (ECGs). AEs were assessed during the study and were classified according to the CTCAE v4.0.
Pharmacokinetics
For pharmacokinetic evaluation of netupitant, blood samples were collected at pre-dose and at 1, 2, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after first administration. Plasma concentrations of netupitant and its active metabolites (M1, M2 and M3) were determined by the validated liquid chromatography/tandem mass spectrometry method. The pharmacokinetic parameters of interest were C max , mean maximum drug plasma concentration, and AUC 0-last , the area under the plasma concentration-time curve calculated from time 0 to the last observed concentration.
Statistical analysis
The primary aim of the study was to determine the dose-response relationship between three different netupitant doses (30, 100 and 300 mg), based on the overall CR rate. It was assumed that the additive effect of netupitant 30 mg on the delayed (24-120 h post chemotherapy) CR rate would be limited; thus, a CR rate of 50% was estimated based on the CR rate observed throughout the period of the Japanese Phase III PROTECT study for the combination of palonosetron with dexamethasone (18) . Based on the results of the Hesketh et al. study (13) , which assessed the recommended clinical dose of netupitant when combined with palonosetron and dexamethasone, the additive effects of netupitant 100 mg and 300 mg were estimated to be 15%.
The primary analysis was carried out using the Mantel extension method for trend adjusted by all allocation adjustment factors (sex, age [<55 vs ≥55 years], type of chemotherapy [CDDP, AC/EC]), with a contrast score of -2, 1 and 1 for the 30-, 100-and 300-mg arms, respectively, and using a one-sided test at the 2.5% significance level. Cochran-Armitage tests were performed as secondary analyses. The primary and secondary efficacy endpoints were assessed using the full analysis set (FAS), which was defined as all eligible patients who received at least one dose of the study drug (3 tablets), who received palonosetron and dexamethasone, and who received the protocol-specified chemotherapy regimen (CDDP or AC/EC). Safety analyses were conducted in patients who received at least one dose of the study drug. The statistical analysis software SAS (SAS version 9.2; SAS Institute Inc, Cary, NC, USA) was used for all analyses except for pharmacokinetics, which were analyzed with Phoenix WinNonlin version 6.3 (Pharsight Corporation, Mountain View, CA, USA).
The sample size required to examine the dose-response relationship among the three arms was calculated using a formula that considers the contrast score. It was determined that 126 patients per arm (378 in total) were required for the FAS with the upper level of significance of 2.5% and a power of 80%. It was assumed that 5% of patients would be excluded from the FAS; therefore, the target sample size was established as 400 patients, to ensure an adequate number of evaluable patients.
Results
Patient characteristics
Between April 2014 and November 2014, a total of 404 patients were enrolled, of which 134 were allocated to the 30-mg arm, 136 to the 100-mg arm, and 134 to the 300-mg arm. Of these, two patients did not receive the study drug and were excluded from the efficacy and safety analyses. The patient population therefore comprised 402 evaluable patients for efficacy and safety: 134 in the 30-mg arm, 135 in the 100-mg arm and 133 in the 300-mg arm (Fig. 1) .
Baseline characteristics were similar among the three dose arms ( Table 1 ). The median age was 62 years (range: 21-78), 56.2% of patients were female, and the majority of patients (~70%) had an ECOG PS score of 0. Across the three arms, 59% of patients received CDDP-based regimens and 41% of patients received an AC/EC regimen.
Efficacy
The primary endpoint of overall CR rate was 64.2%, 60.0% and 54.9% in the 30-, 100-and 300-mg arms, respectively. The acute phase CR rates were 85.8%, 77.0% and 72.2% in the 30-, 100-and 300-mg arms, respectively; in the delayed phase, CR rates were 70.1%, 70.4% and 62.4% in the 30-, 100-and 300-mg arms, respectively. No dose-response relationship was observed over the three different dose arms in the overall (P = 0.9146), acute (P = 0.9949), or delayed (P = 0.7746) phases (Fig. 2) . Daily CR rates experienced by the patients during the 0-120 h interval following administration of 30-, 100-or 300-mg netupitant are presented in Fig. 3 . Similarly, no relationship was observed between dose and response in the secondary endpoints of rates of no vomiting, no nausea and NSN. The rates of no vomiting and NSN were between 67% and 83% in the overall or delayed phases, respectively, irrespective of the netupitant dose used (Table 2 ).
Safety
The number of patients reporting any AE was 134 (100.0%), 130 (96.3%), and 130 (97.7%) in the 30-, 100-and 300-mg arms, respectively. Table 3 lists the AEs occurring in ≥5% of patients in any arm, according to Medical Dictionary for Regulatory Activities -Japan (MedDRA/J) preferred terms. The incidence of AEs was similar between the treatment arms, with constipation, decreased neutrophil count, and decreased appetite the most frequently reported. In total, 43 (32.1%) patients in the 30-mg arm, 35 (25.9%) in the 100-mg arm and 46 (34.6%) in the 300-mg arm reported ADRs. ADRs occurring in ≥5% of patients were constipation (30-mg arm: 22 patients [ . Most of the ADRs were rated as Grade 1 or 2. Three of 134 patients (2.2%), 2 of 135 patients (1.5%), and 3 of 133 patients (2.3%) in the 30-, 100-, and 300-mg arms, respectively, had Grade 3 ADRs, and two patients in the 300-mg arm had Grade 4 ADRs. Serious ADRs (ventricular extrasystoles, acute pancreatitis, increased ALT, increased AST, increased gamma-glutamyltransferase, delirium) occurred in 2 (1.5%) patients in the 30-mg arm and 2 (1.5%) patients in the 300-mg arm. Results from clinical laboratory tests, vital signs and 12-lead ECGs raised no safety concerns.
Pharmacokinetics
The pharmacokinetics of netupitant and its metabolites were assessed in 14, 23 and 12 patients receiving a single oral dose of 30, 100 and 300 mg of netupitant, respectively. After administration of netupitant, plasma concentration of netupitant reached C max at 4 h, followed by a gradual decrease with a half-life of 42-93 h (Fig. 4) . AUC 0-last of netupitant was 3-to 4-fold higher than M1, M2 and M3. C max and AUC 0-last of netupitant and its metabolites increased with the dose increase from 30 mg to 300 mg. Although netupitant and its metabolites had super-proportional increases in AUC 0-last , the degree of non-proportionality was not remarkable. A summary of the pharmacokinetic parameters for each dose is presented in Table 4 .
Discussion
This double-blind, randomized, Phase II study assessed the doseresponse relationship of netupitant in terms of overall CR rate in Japanese cancer patients receiving CDDP-or AC/EC-based HEC. No dose-response relationship was observed between the three tested doses of netupitant (30, 100 and 300 mg; P = 0.9146) in combination with palonosetron (0.75 mg i.v.) and dexamethasone.
These results contrast with those observed in a previous study, which compared three different doses of netupitant (100, 200 and 300 mg) in combination with palonosetron (0.50 mg p.o.) versus palonosetron (0.50 mg p.o.) alone in Caucasian patients on a CDDP-based regimen (13) . Each of those netupitant doses had significantly improved efficacy for the primary endpoint of overall CR rate, compared with palonosetron alone (76.5%); the highest dose of 300 mg had a numerically higher overall CR rate (89.6%) than the two lower doses (87.4% for 100 mg, 87.6% for 200 mg). Nevertheless, there were a couple of differences between the present study and the Hesketh et al. study (13) , primarily inclusion of the 30-mg arm and of patients receiving AC/EC in this study.
When planning this study, there was no clinical evidence for efficacy of 30-mg netupitant. As such, it was anticipated that its efficacy would be similar to that seen with the two higher doses in the acute phase only (based on the assumption of the half-maximal effective concentration). Pharmacokinetic/pharmacodynamic modeling of NK 1 receptor occupancy by netupitant (100, 300 or 450 mg) revealed that maximum receptor occupancy occurs at~6-12 h and sufficient receptor occupancy is maintained over 24-96 h after netupitant administration (11, 12) . Based on this, it can be hypothesized that plasma concentrations following administration of 30-mg oral netupitant may warrant, in the first 6-12 h, an extent of interaction with the brain NK 1 receptors sufficient to justify efficacy mainly in the acute phase, but insufficient in the delayed phase. Hence, the add-on effect on the overall CR rate would be small compared with the effect of 100-and 300-mg netupitant, indicating a suboptimal efficacy for 30-mg netupitant.
A previous CINV research study (19) reported a difference in the pattern of CINV in patients treated with CDDP and non-CDDP HEC. For the non-CDDP HEC population, nausea severity peaked on Day 1, in contrast to patients receiving CDDP HEC. The CINV developed in the acute phase is known to be associated with an increased risk of delayed CINV. In the current study, the unexpected higher acute CR rate with unknown reason observed in the 30-mg arm in the AC/EC population (69.1%, 58.9% and 48.1%, in the 30-, 100-and 300-mg arms, respectively) may have had an effect on the delayed CR rates, and dampened the observed overall doseresponse among the three doses.
In both the overall and acute periods of the efficacy analysis, no dose-response was found for any endpoint among the three arms. Despite the point estimates of response rates generally being numerically higher in the 30-mg group, no significant differences of response rates among each study treatment were found (P > 0.05). Given the extensive evidence showing that NK 1 receptor antagonists, including netupitant, exert their antiemetic effect predominantly in the delayed period (20, 21) , the lack of dose-response in the acute phase is not an unexpected finding. In the delayed period, no dose-response was observed in the CR rate, the no vomiting rate, or the no nausea rate or NSN rate among the three arms. While the point estimates of the CR rates reported by the present study were numerically higher in the 30-mg versus the 100-and 300-mg arms, the point estimate for the rates of no vomiting, no nausea, and NSN were similar among the three arms. These endpoints do not reflect whether rescue medication was used in the delayed period. Nevertheless, given that the study protocol allowed use of rescue medication at the investigator's discretion or in response to the patient's desire, this may suggest an intrinsic subjective variability due to the investigator's decision. Such potential variability among investigators in deciding when to administer rescue medication might impact the study outcomes and account for the lack of dose-response in the overall CR rate observed between the arms. Assessment of daily CR rates and the rationale for using the rescue medications support the above-reported variability in all three netupitant treatment arms.
Examining the pharmacokinetic profile, dose-dependent increases in the plasma exposure for the dose range of 30-300 mg were observed for netupitant and its metabolites. These data suggest that the observed lack of a dose-response relationship for efficacy is not a result of differences in drug exposure.
Finally, the delayed CR rates (62.4-70.1%) observed in the present study are higher than the rate of 56.8%, which was previously reported for the combination of palonosetron (0.75 mg i.v.) and dexamethasone (18) . Although the lack of a placebo arm in the present study prevents us from concluding that the study drug was effective, these data may suggest the potential of netupitant for the prevention of CINV in Japanese patients. In terms of safety, netupitant was well tolerated at all dose levels. The safety profile was similar for the three doses, and was consistent with the safety profile reported in other netupitant studies (13, 16) . The most frequently reported ADRs were hiccups, constipation and headache. The incidence of serious AEs was quite low. Changes in clinical laboratory tests, vital signs and 12-lead ECGs did not suggest an increased safety risk with netupitant.
In conclusion, the optimal dose of netupitant was not determined in this study because no dose-response relationship in terms of overall CR rate was observed between the 30-, 100-and 300-mg doses of netupitant in combination with palonosetron (0.75 mg i.v.) and dexamethasone. At each dose, the safety profile of netupitant was favorable and the incidence of AEs was comparable across the three arms. Further placebo-controlled Phase 2 studies enriched with the findings from this study should be needed to establish the optimal dose of netupitant in this combination in Japanese cancer patients receiving HEC. Considering that the safety of netupitant is comparable, when used at 30, 100 or 300 mg, and that in published studies the dose of 300-mg netupitant was established as the optimal dose for administration in combination with palonosetron (13, 16) , this dose should be included for further investigation in Japanese patients with cancer receiving HEC.
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